Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Interruption or Discontinuation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukaemia: A Retrospective Cohort Study (SPARKLE) in Belgium.
Devos T, Verhoef G, Steel E, Mazure D, Lewalle P, Bron D, Berneman Z, Benghiat FS, Mineur P, Theunissen K, Zachée P, Doyen C, Put N, Lejeune M, Van Eygen K, Havelange V, Reusens M, Pluymers W, Peeters K. Devos T, et al. Acta Haematol. 2019;142(4):197-207. doi: 10.1159/000499329. Epub 2019 Jun 4. Acta Haematol. 2019. PMID: 31163431 Free article. Clinical Trial.
Myelofibrosis patients in Belgium: disease characteristics.
Devos T, Zachée P, Bron D, Noens L, Droogenbroeck JV, Mineur P, Beguin Y, Berneman Z, Benghiat FS, Kentos A, Chatelain C, Demuynck H, Lemmens J, Eygen KV, Theunissen K, Trullemans F, Pierre P, Pluymers W, Knoops L. Devos T, et al. Acta Clin Belg. 2015 Apr;70(2):105-11. doi: 10.1179/2295333714Y.0000000097. Epub 2014 Nov 6. Acta Clin Belg. 2015. PMID: 25380026 Free article.
Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.
Al Assaf C, Van Obbergh F, Billiet J, Lierman E, Devos T, Graux C, Hervent AS, Emmerechts J, Tousseyn T, De Paepe P, Papadopoulos P, Michaux L, Vandenberghe P. Al Assaf C, et al. Among authors: devos t. Haematologica. 2015 Jul;100(7):893-7. doi: 10.3324/haematol.2014.118299. Epub 2015 May 1. Haematologica. 2015. PMID: 25934766 Free PMC article.
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.
Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA, Sarlis NJ, Peng W, Sandor V, Gopalakrishna P, Hmissi A, Stalbovskaya V, Gupta V, Harrison C, Verstovsek S; COMFORT Investigators. Vannucchi AM, et al. Haematologica. 2015 Sep;100(9):1139-45. doi: 10.3324/haematol.2014.119545. Epub 2015 Jun 11. Haematologica. 2015. PMID: 26069290 Free PMC article. Clinical Trial.
A novel approach for BCR-ABL1 standardization to improve International Scale estimation.
Maes B, Bakkus M, Boeckx N, Boone E, Cauwelier B, Denys B, De Schouwer P, Devos T, El Housni H, Hillen F, Jacobs K, Lambert F, Louagie H, Maes MB, Meeus P, Moreau E, Nollet F, Peeters K, Saussoy P, Van Lint P, Vaerman JL, Vaeyens F, Vandepoele K, Vannuffel P, Ver Elst K, Vermeulen K, Bruyndonckx R; Belgian working group on BCR-ABL1 IS standardization. Maes B, et al. Among authors: devos t. Int J Lab Hematol. 2016 Dec;38(6):674-684. doi: 10.1111/ijlh.12556. Epub 2016 Jul 27. Int J Lab Hematol. 2016. PMID: 27460189
The clinical relevance of imatinib plasma trough concentrations in chronic myeloid leukemia. A Belgian study.
Van Obbergh F, Knoops L, Devos T, Beguin Y, Graux C, Benghiat F, Kargar-Samani K, Bauwens D, Efira A, Dubois C, Springael C, Montfort L, Connerotte T, Capron A, Delannoy A, Wallemacq P. Van Obbergh F, et al. Among authors: devos t. Clin Biochem. 2017 May;50(7-8):452-454. doi: 10.1016/j.clinbiochem.2016.12.006. Epub 2016 Dec 22. Clin Biochem. 2017. PMID: 28017570 Free article.
136 results